---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Pathophysiology"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Pathophysiology. Topics: Overview: limited distinction from treatment-responsive depression, Stress response: hypothalamic-pituitary-adrenal axis, Inflammation: peripheral C-reactive protein, Glutamate signaling and glial cells, and 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Overview: limited distinction from treatment-responsive depression

> “TRD patients exhibit the same diversity of symptoms, course, history and co-occurring conditions as for treatment-responsive MDD.”
> “It must be emphasized that the following mechanisms and etiological processes have not yet been compared sufficiently between TRD versus treatment-responsive MDD. Establishing areas of similarities and differences between the two is a high priority of current research.”

Source: [Akil et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729118/)

<a id="topic-2.2.1.4-2"></a>

### Stress response: hypothalamic-pituitary-adrenal axis

> “Studies of the neurobiology of depression, including TRD, focus largely on the association between stress and depression, with the hope that an understanding of the biological pathways that link stress to depression would inform on the pathophysiology of the disorder.”

Source: [Akil et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729118/)

> “Altered functioning of the hypothalamic-pituitary-adrenal (HPA) axis has been demonstrated in patients with treatment-resistant depression, although studies have often conflated patients with unipolar and bipolar depression.”
> “Patients with TRUD had higher total cortisol production in the morning hours compared to controls (AUCg, p = 0.01), while they did not differ in terms of the awakening response (AUCi, p = 0.28).”

Source: [Markopoulou et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8076168/)

<a id="topic-2.2.1.4-3"></a>

### Inflammation: peripheral C-reactive protein

> “Compared with healthy volunteers, BMI-corrected CRP was significantly elevated in the treatment-resistant group (P = 0.007; Cohen's d = 0.47); but not significantly so in the treatment-responsive (d = 0.29) and untreated (d = 0.18) groups.”
> “CRP was elevated in patients with MDD, and more so in treatment-resistant patients. Other phenotypes associated with elevated CRP included childhood adversity and specific depressive and anxious symptoms.”

Source: [Chamberlain et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6124647/)

> “Immune-related mechanisms are increasingly recognised as important in the pathophysiology of depression, particularly treatment-resistant depression (TRD).”

Source: [Strawbridge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244173/)

<a id="topic-2.2.1.4-4"></a>

### Glutamate signaling and glial cells

> “Although excessive glutamatergic neurotransmission and consequent excitotoxicity were considered a major cause of TRD, recent evidence suggests that the extrasynaptic glutamatergic receptor signal pathway mainly contributes to the detrimental effects of TRD.”
> “Glial cells such as microglia and astrocytes, early life adversity, and glucocorticoid receptor dysfunction participate in complex cross-talk.”
> “Excessive microglial activation and the inflammatory process cause astrocyte glutamatergic dysfunction, which in turn activates microglial function.”

Source: [Kim and Na (2016)](https://pubmed.ncbi.nlm.nih.gov/27046518/)

<a id="topic-2.2.1.4-5"></a>

### Brain networks: neuroimaging differences between TRD and non-TRD

> “Our main findings are that patients with TRD show 1) reduced functional connectivity (FC) within the default mode network (DMN), 2) reduced FC between components of the DMN and other brain areas, and 3) hyperactivity of DMN regions. In addition, aberrant activity and FC in the occipital lobe may play a role in TRD.”
> “The main limitations of most studies were related to inherent confounding factors for comparing TRD with non-TRD, such as differences in disease chronicity/severity and medication history.”

Source: [Runia et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34890601/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
